A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003531/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
提供机构：
Vivli
创建时间：
2019-04-12
